Ipamorelin: Complete Research Guide (2026)

Ipamorelin is one of the most extensively studied selective growth-hormone secretagogues in preclinical research. Developed by Novo Nordisk in 1998 as a purified analog of the earlier GHRP family, it stands out because of a single clean pharmacological property: it triggers pulsatile GH release from the pituitary without meaningfully elevating cortisol, prolactin, or ACTH. That selectivity is what has made it the reference GHRP compound in growth-hormone axis studies for more than two decades. This 2026 guide covers ipamorelin's molecular structure, mechanism of action at the ghrelin receptor, preclinical research applications, reconstitution protocols, comparisons to related peptides (Sermorelin, Hexarelin, GHRP-6), the EU regulatory framework, and where to buy ipamorelin in Europe under the Research Use Only (RUO) framework.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, where Aib is the non-proteinogenic residue α-aminoisobutyric acid. Its compact five-residue structure, combined with D-amino acid substitutions, gives it a favorable receptor-binding and metabolic profile:

History and scientific context

The GHRP (Growth Hormone Releasing Peptide) family began with the discovery of GHRP-6 in the 1980s by Cyril Bowers, followed by GHRP-2, hexarelin and related analogs. All shared the ability to trigger pituitary GH release via a receptor that was, at the time, not yet identified. That receptor — the ghrelin receptor GHS-R1a — was cloned in 1996, and its endogenous ligand, ghrelin, was identified in 1999. The GHRPs were, in effect, discovered before the receptor and the natural ligand they mimicked.

By the late 1990s, Novo Nordisk was actively searching for a next-generation GHRP that would preserve the GH-releasing effect while removing the off-target hormonal noise seen with earlier compounds — specifically the concomitant rise in cortisol, prolactin, and ACTH. In 1998, their team published on ipamorelin (NNC 26-1291), describing it as a highly potent GH secretagogue with a selectivity profile that other GHRPs did not match. Since then, ipamorelin has been the reference compound for GHRP-6-analog research whenever selectivity for the GH axis is the priority.

Mechanism of action

Ipamorelin's primary mechanism is agonist activity at the ghrelin receptor GHS-R1a on somatotroph cells of the anterior pituitary. When ipamorelin binds GHS-R1a, it triggers intracellular signaling (Gq / phospholipase C / IP3 / Ca²⁺) that leads to a sharp, pulsatile release of stored endogenous growth hormone.

The distinctive property described in preclinical studies is receptor selectivity. In comparative work against GHRP-6 and hexarelin, ipamorelin produced comparable GH release without meaningfully raising:

• Cortisol — GHRP-6 and hexarelin measurably increase cortisol, ipamorelin does not.
• Prolactin — same pattern.
• ACTH — same pattern.

This clean receptor profile is why ipamorelin is preferred in preclinical designs that need to isolate GH-axis effects from broader stress-hormone effects. When paired with a GHRH analog such as CJC-1295 or Sermorelin, ipamorelin's pulse rides on top of an elevated GHRH-driven baseline, and the two pathways are additive rather than redundant.

Important: All of the above is described in preclinical models. Pepspan supplies ipamorelin (as part of the CJC-1295 + Ipamorelin blend) strictly under Research Use Only (RUO) — it is not an authorized medicine, is not intended for human consumption, and Pepspan does not provide any clinical guidance.

Research applications

Ipamorelin appears in several distinct preclinical research streams:

1. Growth-hormone axis modulation

The primary and most documented use. Ipamorelin is used to study pulsatile GH release, GHS-R1a receptor pharmacology, and the interaction between the ghrelin and GHRH systems in the pituitary. It is often the reference GHRP against which newer secretagogues are benchmarked because of its selectivity.

2. Muscle and recovery research

Downstream of pulsatile GH release comes IGF-1 activation from the liver, which is central to musculoskeletal anabolism and connective-tissue turnover. Preclinical models have used ipamorelin — often stacked with CJC-1295 — to explore GH/IGF-1-mediated pathways in muscle and recovery contexts.

3. Aging and longevity research

Somatopause — the age-related decline in endogenous GH pulsatility — is a well-described phenomenon. Ipamorelin is used in aging-model rodents to study whether restoring pulsatile GH release changes markers of tissue maintenance, body composition, or sarcopenia progression.

4. Appetite and gastric motility

Because ipamorelin binds the ghrelin receptor, it has been studied for the non-GH effects of GHS-R1a activation — including appetite regulation and gastrointestinal motility. Ipamorelin was in fact investigated in early clinical work for post-operative ileus before that program was discontinued.

Reconstitution and dosing protocols

Ipamorelin is shipped as a lyophilized white powder (typically as part of the CJC-1295 + Ipamorelin blend at Pepspan). Standard research reconstitution protocol:

1. Bring both vials to room temperature (20-25°C) before opening. Cold vials can cause moisture condensation on the powder.
2. Calculate diluent volume for the target concentration. Examples:
   • 5mg + 2ml bac water = 2.5 mg/ml
   • 10mg (blend) + 2ml bac water = 5 mg/ml total peptide
3. Aseptic technique: disinfect both vial septa with 70% isopropanol. Use a sterile syringe.
4. Inject the bacteriostatic water slowly along the inner wall of the ipamorelin vial — never directly onto the powder.
5. Swirl gently until fully dissolved. Do not shake vigorously.
6. Store immediately at 2-8°C. Do not leave at room temperature. Use within 28 days.

In preclinical animal work, ipamorelin doses reported in the literature typically fall in the range of 3-100 µg/kg subcutaneously, often administered once or twice daily to reproduce pulsatile GH release patterns. When combined with CJC-1295, the two peptides are usually reconstituted together for simplicity. Pepspan does not provide human-use dosing recommendations.

Ipamorelin vs GHRP-6, Hexarelin and Sermorelin

Ipamorelin often gets grouped with peptides that work through different mechanisms. The clean distinctions:

• Ipamorelin vs GHRP-6: both are GHRPs and both activate GHS-R1a. Ipamorelin was engineered to keep the GH-releasing potency of GHRP-6 while removing the off-target cortisol, prolactin and ACTH elevation. Ipamorelin is the more selective compound.
• Ipamorelin vs Hexarelin: hexarelin is another GHRP with high GH-releasing potency but even more pronounced cortisol and prolactin elevation than GHRP-6. Preclinical work also flagged receptor desensitization concerns with sustained hexarelin exposure. Ipamorelin's clean profile is why researchers now default to it for GHS-R1a agonism studies.
• Ipamorelin vs Sermorelin (and CJC-1295): this is a class distinction. Sermorelin and CJC-1295 are GHRH analogs — they bind the GHRH receptor on somatotrophs. Ipamorelin is a GHRP analog that binds the ghrelin receptor GHS-R1a. Different receptors, complementary downstream signaling. This is why GHRH + GHRP stacking (e.g. CJC-1295 + Ipamorelin) is additive.

Why Ipamorelin is stacked with CJC-1295

The rationale for the CJC-1295 + Ipamorelin blend follows directly from the receptor pharmacology above:

• CJC-1295 is a long-acting GHRH analog. It binds the GHRH receptor on pituitary somatotrophs and raises the tonic baseline of endogenous GH availability.
• Ipamorelin binds the separate ghrelin receptor GHS-R1a and, on top of that elevated baseline, drives a sharper pulsatile GH release.
• The two pathways converge on the same output — endogenous GH release — but through independent receptor systems, so their effects are additive rather than competitive.

This is why the CJC-1295 + Ipamorelin combination has become the reference GH-axis research stack, and why Pepspan supplies it as a single lyophilized blend rather than two separate vials — most preclinical protocols use them together anyway.

Where to buy Ipamorelin in Europe

In Europe, ipamorelin is sold as a laboratory reagent under Research Use Only (RUO). It is not an authorized medicine under the EMA. It does not require a medical prescription for research purchases. European pharmacies do not stock ipamorelin — the realistic acquisition route is specialized research-peptide suppliers.

Pepspan supplies ipamorelin as part of the CJC-1295 + Ipamorelin blend — a 10mg total lyophilized vial containing both peptides at the ratio used in the reference preclinical protocols. We do not currently offer a standalone ipamorelin SKU because virtually every research application uses the two peptides together, and shipping them pre-blended reduces reconstitution error and cost.

Pepspan pricing (2026):

• CJC-1295 + Ipamorelin 10mg blend: 79€ per vial (retail)
• Wholesale (10+ vials): automatic 20% discount = 63.20€ per unit
• Free shipping: orders over 100€
• EU delivery: European stock, ships from Europe, no customs friction inside the EU/EEA
• Janoshik COA included with every order — HPLC purity, MS identity, endotoxin, microbial screening

For research clinics, laboratories or distributors with recurring volume, Pepspan offers custom terms — contact [email protected].

Regulatory framework in Europe

Ipamorelin is sold legally across the 27 EU member states and EEA countries as a laboratory reagent under the Research Use Only (RUO) framework. It is not authorized as a medicinal product by the EMA (European Medicines Agency) or by any national medicines regulator. It cannot be marketed, prescribed, or used for human or animal consumption.

By purchasing ipamorelin, the customer confirms:

• Being a qualified researcher, laboratory professional, or working in R&D
• Using the product exclusively for scientific research
• Understanding and accepting the RUO framework and Pepspan's disclaimers

Detailed legal framework: Legal status of research peptides in Europe.

Buy Ipamorelin at Pepspan

Frequently asked questions

What is Ipamorelin?

A selective synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, ~711.86 Da) developed by Novo Nordisk in 1998. It is a GHRP-6 analog and ghrelin receptor (GHS-R1a) agonist that triggers pulsatile GH release without meaningfully elevating cortisol, prolactin or ACTH.

How does Ipamorelin work?

It binds the ghrelin receptor GHS-R1a on pituitary somatotrophs and drives pulsatile endogenous GH release. Its distinctive property vs GHRP-6 and hexarelin is that it does not meaningfully stimulate cortisol, prolactin or ACTH. Plasma half-life ~2 hours in preclinical species.

Where to buy Ipamorelin in Europe?

Pepspan supplies Ipamorelin as part of the CJC-1295 + Ipamorelin 10mg blend at 79€/vial, EU stock, Janoshik COA per batch. Ships across the 27 EU/EEA countries with no customs friction. Wholesale 10+ vials = automatic 20% discount (63.20€/unit). No prescription required under the RUO framework.

Is Ipamorelin legal in Europe?

Yes. Sold legally across the EU/EEA as a laboratory reagent under Research Use Only (RUO). Not authorized as a medicine by the EMA. No prescription needed for research purchases. Buyer must be a qualified researcher.

What is the typical preclinical dosage?

Preclinical animal research typically uses 3-100 µg/kg subcutaneously, once or twice daily to reproduce pulsatile GH release. When combined with CJC-1295 the two are reconstituted together. Pepspan does not provide human-use dosing recommendations.

How to store Ipamorelin?

Lyophilized: 4°C for months / -20°C for years. Reconstituted: 2-8°C, use within 28 days. Never freeze reconstituted solution. Protect from direct light.

Ipamorelin vs Sermorelin — what is the difference?

Sermorelin is a GHRH analog — it mimics GHRH and binds the GHRH receptor. Ipamorelin is a GHRP analog — it mimics ghrelin and binds the ghrelin receptor GHS-R1a. Different receptors, complementary pathways. This is why they are stacked (as GHRH + GHRP) in research protocols.

Why is Ipamorelin combined with CJC-1295?

CJC-1295 (GHRH analog) raises the tonic GH baseline; Ipamorelin (ghrelin receptor agonist) drives a sharper pulsatile release on top. The two receptor pathways are complementary, so combined effect exceeds either peptide alone. This is why the blend is the most studied GH-axis research stack.

How to reconstitute Ipamorelin?

Room temperature → calculate diluent volume (5mg + 2ml = 2.5 mg/ml) → inject bacteriostatic water along the inner vial wall (never onto the powder) → swirl gently → store 2-8°C, use within 28 days.